



LKT Laboratories, Inc.

Afuresertib

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID A225822

CAS No. 1047644-62-1

Chemical Name

Synonym GSK-2110183C, GSK-2110183

Formula $C_{18}H_{17}Cl_2FN_4OS$

Formula Wt. 427.32

Melting Point


Purity $\geq 98\%$

Solubility

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description Afuresertib is an inhibitor of Akt, a serine/threonine kinase. In addition to showing efficacy in clinical trials as a monotherapy against hematological malignancies, afuresertib has been effective against multiple myeloma. When used in combination with pomalidomide plus dexamethasone, afuresertib exhibited antitumor activity in multiple myeloma cells. It has also shown efficacy in patients with malignant pleural mesothelioma.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
A225822	5 mg	\$116.90
A225822	25 mg	\$357.00
A225822	100 mg	\$941.00

References Kinoshita S., Ri M., et al. Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma. *Oncol Lett.* 15(6):9450-56 (2018). PMID: 29927335.

Yamaji M., Ota A., et al. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. *Cancer Med.* 6(11):2646-59 (2017). PMID: 28960945.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.